Antiplatelet, anticoagulant, and profibrinolytic activities of cudratricusxanthone A

Archives of Pharmacal Research

Volumn 37, Issue 8, 2014, Pages 1069-1078

  Yoo, Hayoung ^a   Ku, Sae Kwang ^b   Lee, Wonhwa ^a,c   Kwak, Soyoung ^a   Baek, Young Doo ^d   Min, Byung Woon ^e   Jeong, Gil Saeng ^f   Bae, Jong Sup ^a  

^a Kyungpook National University   (South Korea)

^b Daegu Haany University   (South Korea)

^c Kyungpook National University School of Medicine   (South Korea)

^d Daegu Health College   (South Korea)

^e Hanlyo University   (South Korea)

^f Keimyung University   (South Korea)

Author keywords

Anticoagulant; Cudratricusxanthone A; Fibrinolysis; Prenylated xanthone

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BLOOD CLOTTING FACTOR 10A; CUDRATRICUSXANTHONE A; FIBRINOLYTIC AGENT; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBIN; XANTHONE DERIVATIVE;

ANIMAL; BLOOD; BLOOD CLOTTING; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; HUMAN; INSTITUTE FOR CANCER RESEARCH MOUSE; ISOLATION AND PURIFICATION; MALE; METABOLISM; MORACEAE; MOUSE; PLANT ROOT; THROMBOCYTE AGGREGATION; UMBILICAL VEIN ENDOTHELIAL CELL;

ANIMALS; ANTICOAGULANTS; BLOOD COAGULATION; CELL SURVIVAL; FACTOR XA; FIBRINOLYTIC AGENTS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MALE; MICE; MICE, INBRED ICR; MORACEAE; PLANT ROOTS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; THROMBIN; XANTHONES;

EID: 84887307282     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-013-0290-4     Document Type: Article

References (29)

1. Chung, M.I., J.R. Weng, J.P. Wang, C.M. Teng, and C.N. Lin. 2002. Antiplatelet and anti-inflammatory constituents and new oxygenated xanthones from Hypericum geminiflorum. Planta Medica 68: 25-29.
2. Correia-Da-Silva, M., E. Sousa, B. Duarte, F. Marques, F. Carvalho, L.M. Cunha-Ribeiro, and M.M. Pinto. 2011. Polysulfated xanthones: multipathway development of a new generation of dual anticoagulant/antiplatelet agents. Journal of Medicinal Chemistry 54: 5373-5384.
3. Dahlback, B. 2000. Blood coagulation. Lancet 355: 1627-1632.
4. Davie, E.W. 1995. Biochemical and molecular aspects of the coagulation cascade. Thrombosis Haemostasis 74: 1-6.
5. Davie, E.W., K. Fujikawa, and W. Kisiel. 1991. The coagulation cascade: initiation, maintenance, and regulation. Biochemistry 30: 10363-10370.
6. Dejana, E., A. Callioni, A. Quintana, and G. De Gaetano. 1979. Bleeding time in laboratory animals. II - A comparison of different assay conditions in rats. Thrombosis Research 15: 191-197.
7. Ghosh, S., M. Ezban, E. Persson, U. Pendurthi, U. Hedner, and L.V. Rao. 2007. Activity and regulation of factor VIIa analogs with increased potency at the endothelial cell surface. Journal of Thrombosis and Haemostasis 5: 336-346.
8. Hamaguchi, E., T. Takamura, A. Shimizu, and Y. Nagai. 2003. Tumor necrosis factor-alpha and troglitazone regulate plasminogen activator inhibitor type 1 production through extracellular signal-regulated kinase- and nuclear factor-kappaB-dependent pathways in cultured human umbilical vein endothelial cells. Journal of Pharmacology and Experimental Therapeutics 307: 987-994.
9. Hwang, J.H., S.S. Hong, X.H. Han, J.S. Hwang, D. Lee, H. Lee, Y.P. Yun, Y. Kim, J.S. Ro, and B.Y. Hwang. 2007. Prenylated xanthones from the root bark of Cudrania tricuspidata. Journal of Natural Products 70: 1207-1209.
10. Jeong, G.S., D.S. Lee, and Y.C. Kim. 2009. Cudratricusxanthone A from Cudrania tricuspidata suppresses pro-inflammatory mediators through expression of anti-inflammatory heme oxygenase-1 in RAW264.7 macrophages. International Immunopharmacology 9: 241-246.
11. Kim, D.C., S.K. Ku, and J.S. Bae. 2012a. Anticoagulant activities of curcumin and its derivative. BMB Rep 45: 221-226.
12. Kim, S.Y., S. Kim, J.M. Kim, E.H. Jho, S. Park, D. Oh, and H.S. Yun-Choi. 2011. PKC inhibitors RO 31-8220 and Go 6983 enhance epinephrine-induced platelet aggregation in catecholamine hypo-responsive platelets by enhancing Akt phosphorylation. BMB Reports 44: 140-145.
13. Kim, T.H., S.K. Ku, and J.S. Bae. 2012b. Antithrombotic and profibrinolytic activities of eckol and dieckol. Journal of Cellular Biochemistry 113: 2877-2883.
14. Kim, T.J., H.J. Han, S.S. Hong, J.H. Hwang, B.Y. Hwang, H.S. Yoo, Y.R. Jin, J.J. Lee, J.Y. Yu, K.H. Lee, B.W. Kang, and Y.P. Yun. 2007. Cudratricusxanthone A isolated from the root bark of Cudrania tricuspidata inhibits the proliferation of vascular smooth muscle cells through the suppression of PDGF-receptor beta tyrosine kinase. Biological and Pharmaceutical Bulletin 30: 805-809.
15. Lee, K.H. 2000. Research and future trends in the pharmaceutical development of medicinal herbs from Chinese medicine. Public Health Nutrition 3: 515-522.
16. Lee, W., E.J. Yang, S.K. Ku, K.S. Song, and J.S. Bae. 2012. Anticoagulant activities of oleanolic acid via inhibition of tissue factor expressions. BMB Reports 45: 390-395.
17. Li, Y., Z.J. Qian, B. Ryu, S.H. Lee, M.M. Kim, and S.K. Kim. 2009. Chemical components and its antioxidant properties in vitro: an edible marine brown alga Ecklonia cava. Bioorganic and Medicinal Chemistry 17: 1963-1973.
18. Lin, C.N., H.K. Hsieh, S.J. Liou, H.H. Ko, H.C. Lin, M.I. Chung, F.N. Ko, H.W. Liu, and C.M. Teng. 1996. Synthesis and antithrombotic effect of xanthone derivatives. Journal of Pharmacy and Pharmacology 48: 887-890.
19. Lopez, S., F. Peiretti, B. Bonardo, I. Juhan-Vague, and G. Nalbone. 2000. Effect of atorvastatin and fluvastatin on the expression of plasminogen activator inhibitor type-1 in cultured human endothelial cells. Atherosclerosis 152: 359-366.
20. Nowak, P., H.M. Zbikowska, M. Ponczek, J. Kolodziejczyk, and B. Wachowicz. 2007. Different vulnerability of fibrinogen subunits to oxidative/nitrative modifications induced by peroxynitrite: functional consequences. Thrombosis Research 121: 163-174.
21. Philip-Joet, F., M.C. Alessi, C. Philip-Joet, M. Aillaud, J.R. Barriere, A. Arnaud, and I. Juhan-Vague. 1995. Fibrinolytic and inflammatory processes in pleural effusions. European Respiratory Journal 8: 1352-1356.
22. Quinn, C., J. Hill, and H. Hassouna. 2000. A guide for diagnosis of patients with arterial and venous thrombosis. Clinical and Laboratory Science 13: 229-238.
23. Qureshi, S.H., C. Manithody, J.S. Bae, L. Yang, and A.R. Rezaie. 2008. Autolysis loop restricts the specificity of activated protein C: analysis by FRET and functional assays. Biophysical Chemistry 134: 239-245.
24. Rajtar, G., D. Zolkowska, Z. Kleinrok, and H. Marona. 1999. Antiplatelets activity of some xanthone derivatives. Acta Poloniae Pharmaceutica 56: 319-324.
25. Rao, L.V., S.I. Rapaport, and M. Lorenzi. 1988. Enhancement by human umbilical vein endothelial cells of factor Xa-catalyzed activation of factor VII. Blood 71: 791-796.
26. Schleef, R.R., M.P. Bevilacqua, M. Sawdey, M.A. Gimbrone Jr, and D.J. Loskutoff. 1988. Cytokine activation of vascular endothelium. Effects on tissue-type plasminogen activator and type 1 plasminogen activator inhibitor. Journal of Biological Chemistry 263: 5797-5803.
27. Sugo, T., C. Nakamikawa, S. Tanabe, and M. Matsuda. 1995. Activation of prothrombin by factor Xa bound to the membrane surface of human umbilical vein endothelial cells: its catalytic efficiency is similar to that of prothrombinase complex on platelets. Journal of Biochemistry 117: 244-250.
28. Tian, Y.H., H.C. Kim, J.M. Cui, and Y.C. Kim. 2005. Hepatoprotective constituents of Cudrania tricuspidata. Archives of Pharmacal Research 28: 44-48.
29. Zou, Y.S., A.J. Hou, G.F. Zhu, Y.F. Chen, H.D. Sun, and Q.S. Zhao. 2004. Cytotoxic isoprenylated xanthones from Cudrania tricuspidata. Bioorganic and Medicinal Chemistry 12: 1947-1953.